Back to top

Image: Bigstock

Theravance Biopharma, Inc.

Read MoreHide Full Article

Theravance has only one marketed product in its portfolio, Vibativ. Though Vibativ continues to perform well, the company’s sole dependence on the drug for growth is concerning. Moreover, its pipeline programs targeting the therapeutic areas are highly competitive which could affect the company’s operating results. Also, any agreement termination might be a huge setback for the company, as had been the case in the past. However, we are positive on Theravance’s efforts to expand the Vibativ’s label, which, if approved for additional indications, would be commercially significant. Further, Theravance’s collaboration agreement with Mylan for revefenacin, is a big positive. Its shares have outperformed the industry so far this year.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Theravance Biopharma, Inc. (TBPH) - free report >>

Published in